Canada - English - Health Canada

janssen inc - ofloxacin - tablet - 300mg - ofloxacin 300mg - quinolones

Canada - English - Health Canada

janssen inc - ofloxacin - tablet - 400mg - ofloxacin 400mg - quinolones

Canada - English - Health Canada

glaxosmithkline inc - urea; hydrocortisone acetate - cream - 10%; 1% - urea 10%; hydrocortisone acetate 1% - anti-inflammatory agents

Canada - English - Health Canada

glaxosmithkline inc - hydrocortisone acetate; urea - lotion - 1%; 10% - hydrocortisone acetate 1%; urea 10% - anti-inflammatory agents

Canada - English - Health Canada

paladin labs inc. - testosterone - gel - 1% - testosterone 1% - androgens

Canada - English - Health Canada

nu-pharm inc - lamotrigine - tablet - 25mg - lamotrigine 25mg - miscellaneous anticonvulsants

Canada - English - Health Canada

nu-pharm inc - lamotrigine - tablet - 100mg - lamotrigine 100mg - miscellaneous anticonvulsants

Canada - English - Health Canada

nu-pharm inc - lamotrigine - tablet - 150mg - lamotrigine 150mg - miscellaneous anticonvulsants

United States - English - NLM (National Library of Medicine)

rxhomeo private limited d.b.a. rxhomeo, inc - jacobaea vulgaris (unii: 31m57289i3) (juniperus sabina leafy twig - unii:z5bex9k2g1) - wry neck condition listed above or as directed by the physician

United States - English - NLM (National Library of Medicine)

jacobus pharmaceutical company,inc - amifampridine (unii: ru4s6e2g0j) (amifampridine - unii:ru4s6e2g0j) - ruzurgi is indicated for the treatment of lambert-eaton myasthenic syndrome (lems) in patients 6 to less than 17 years of age. ruzurgi is contraindicated in patients with: - a history of seizures [see warnings and precautions (5.1)] - hypersensitivity to amifampridine or another aminopyridine [see warnings and precautions (5.2)] risk summary there are no data on the developmental risk associated with the use of ruzurgi in pregnant women. animal studies to assess the potential adverse effects of amifampridine on embryofetal development have not been conducted. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. risk summary there are no data on the presence of amifampridine or the 3-n-acetyl-amifampridine metabolite in human milk, the effects on the breastfed infant, or the effects on mi